×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IPSEY – ipsen sa s/adr (US:AMEX)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IPSEY
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/7
08:42 am
ipsey
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
Neutral
Report
Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue
11/3
06:11 pm
ipsey
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
Medium
Report
IPSEN (OTCMKTS:IPSEY) had its "buy" rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
10/23
07:32 am
ipsey
Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
Low
Report
Ipsen Launches Educational Initiative to Support Teens and Young Adults Moving From Pediatric to Adult Healthcare
10/22
04:00 am
ipsey
EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
Neutral
Report
EQT Life Sciences' ImCheck Therapeutics to be acquired by Ipsen in a transaction valued at up to EUR 1 billion
10/22
01:05 am
ipsey
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
Neutral
Report
Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance
10/22
01:00 am
ipsey
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
Neutral
Report
Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline
9/22
01:00 am
ipsey
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
Neutral
Report
Ipsen’s LANTIC Phase II in aesthetics delivers a first-in-class, differentiated long-acting clinical profile for IPN10200, enabling the initiation of Phase III
9/19
07:59 am
ipsey
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Low
Report
Bylvay® (odevixibat) approved in Japan for rare liver disease PFIC
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
4/20
Ipsen Announces Positive Topline Results From Pivotal Phase III CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Previously Untreated Advanced Renal Cell Carcinoma
5.8%
4/22 Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact 5.5%
4/27 Photocure Regains Worldwide Rights of Hexvix 3.8%
5/20 IPSEN S A/S (OTCMKTS: IPSEY) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. 1.9%
7/23 Ipsen: Disclosure of Transactions in Own Shares Between 15/07/2019 And 19/07/2019 1.8%
5/28 Combined Shareholders’ Meeting of IPSEN S.A. held on 28 May 2019 1.3%
4/1 Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19 1.2%
4/14 Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company 1.0%
6/17 IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company 1.0%
5/13 IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company 1.0%
4/22 Ipsen Reports Solid Sales Growth in First Quarter 2020 With Limited COVID-19 Impact 5.5%
4/27 Photocure Regains Worldwide Rights of Hexvix 3.8%
5/20 IPSEN S A/S (OTCMKTS: IPSEY) was upgraded by analysts at JPMorgan Chase & Co. from an "underweight" rating to a "neutral" rating. 1.9%
7/23 Ipsen: Disclosure of Transactions in Own Shares Between 15/07/2019 And 19/07/2019 1.8%
5/28 Combined Shareholders’ Meeting of IPSEN S.A. held on 28 May 2019 1.3%
4/1 Ipsen Donates €2 Million to the Institut Pasteur to Support Research on COVID-19 1.2%
4/14 Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company 1.0%
6/17 IPSEN: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company 1.0%
5/13 IPSEN: Monthly information regarding the total number of voting rights and total number of shares of the Company 1.0%
TOP News Decliners
1/24
Ipsen’s palovarotene clinical program in fibrodysplasia ossificans progressiva reaches prespecified interim analysis futility criteria
-23.2%
12/6 Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies -13.7%
7/28 Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.0%
1/9 IPSEN S A/S (OTCMKTS: IPSEY) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. -5.2%
12/18 Ipsen Announces Departure of David Meek as Chief Executive Officer -5.1%
12/6 Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns [Yahoo! Finance News] -5.0%
3/3 IPSEN S A/S (OTCMKTS: IPSEY) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.6%
2/13 Ipsen Presents Its 2019 Results, Provides 2020 Guidance and Updates 2022 Financial Outlook -4.2%
3/11 Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly -2.9%
3/17 Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company -2.7%
12/6 Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies -13.7%
7/28 Ipsen S.A. ADR (IPSEY) CEO David Meek on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -6.0%
1/9 IPSEN S A/S (OTCMKTS: IPSEY) was downgraded by analysts at Jefferies Financial Group Inc from a "buy" rating to a "hold" rating. -5.2%
12/18 Ipsen Announces Departure of David Meek as Chief Executive Officer -5.1%
12/6 Ipsen Plunges as FDA Halts Bone Drug Trial in Children on Safety Concerns [Yahoo! Finance News] -5.0%
3/3 IPSEN S A/S (OTCMKTS: IPSEY) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -4.6%
2/13 Ipsen Presents Its 2019 Results, Provides 2020 Guidance and Updates 2022 Financial Outlook -4.2%
3/11 Ipsen Data Presented during ENETS Annual Conference 2020 Capture New Patient and Healthcare Professional Insights in the Treatment of NETs and Acromegaly -2.9%
3/17 Ipsen: Monthly Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company -2.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: